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Abstract
Background: Colorimetric albumin assays based on 
binding to bromocresol purple (BCP) and bromocresol 
green (BCG) yield different results in chronic kidney 
disease. Altered dye binding of carbamylated albumin has 
been suggested as a cause. In the present study, a detailed 
analysis was carried out in which uremic toxins, acute 
phase proteins and Kt/V, a parameter describing hemo-
dialysis efficiency, were compared with colorimetrically 
assayed (BCP and BCG) serum albumin.
Methods: Albumin was assayed using immunonephelom-
etry on a BN II nephelometer and colorimetrically based 
on, respectively, BCP and BCG on a Modular P analyzer. 
Uremic toxins were assessed using high-performance 
liquid chromatography. Acute phase proteins (C-reactive 
protein and α1-acid glycoprotein) and plasma protein α2-
macroglobulin were assayed nephelometrically. In paral-
lel, Kt/V was calculated.
Results: Sixty-two serum specimens originating from 
hemodialysis patients were analyzed. Among the uremic 
toxins investigated, total para-cresyl sulfate (PCS) showed 
a significant positive correlation with the BCP/BCG ratio. 
The serum α1-acid glycoprotein concentration correlated 
negatively with the BCP/BCG ratio. The BCP/BCG ratio 
showed also a negative correlation with Kt/V.
Conclusions: In renal insufficiency, the BCP/BCG ratio of 
serum albumin is affected by multiple factors: next to car-
bamylation, uremic toxins (total PCS) and α1-acid glyco-
protein also play a role.
Keywords: albumin; bromocresol green; bromocresol 
purple; carbamylation; para-cresyl sulfate; uremic toxins.
Introduction
Albumin is an important marker for predicting nutritional 
status, morbidity and mortality in hemodialysis patients 
[1]. Colorimetric serum albumin assays based on binding to 
bromocresol purple (BCP) and bromocresol green (BCG) are 
known to yield discrepant results in end-stage renal disease 
(ESRD) [2]. Dyes may bind to albumin due to weak van der 
Waals forces. In the majority of the ESRD population, the 
serum albumin concentrations obtained with BCG appear 
to be more reliable in comparison with BCP-based measure-
ments, which yield falsely low serum albumin concentra-
tions [3–6]. However, in a recent paper, evaluating 24 serum 
albumin measurement procedures (3  immunochemical, 9 
BCG and 12 BCP methods) in patients without renal disease 
and with kidney failure before hemodialysis, larger biases 
were observed with BCG than with BCP, when compared with 
the reference measurement procedure (Roche Tina-quant 
immunochemical procedure). Thus, BCP was proposed as the 
preferred agent for standardization of serum albumin results 
using dye-binding methods [7]. In patients with a nephrotic 
syndrome, the increased amount of α2-macroglobulin is a 
major factor for positive bias of BCG-based serum albumin 
assays [8]. As BCG shows an affinity for α- and β-globulins 
[9, 10], BCP should be used to determine the serum albumin 
concentrations in nephrotic syndrome [8].
At this moment, the underlying reasons for the dis-
crepancy between BCG- and BCP-based serum albumin 
assays are not yet completely resolved. As progressive renal 
insufficiency induces many changes and causes accumu-
lation of several compounds in plasma, the binding of 
serum albumin to dyes in ESRD patients may be simul-
taneously affected by many factors. Carbamylation has 
been identified as one of the confounders of BCP-based 
serum albumin assays as blood urea concentrations rise 
in advanced renal insufficiency. Carbamylation is a non-
enzymatic, posttranslational modification of proteins by 
isocyanate, a urea dissociation product [11]. Cyanate binds 
irreversibly to proteins and neutralizes positively charged 
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lysines, leading to changes in protein structures [12]. The 
two binding sites of albumin for BCP possess a lysine 
residue, which can be carbamylated by isocyanate, result-
ing in lower measured serum albumin concentrations [2, 
13]. Carbamylation of albumin reduces its ability to bind 
ligands, especially drugs [14]. Assessing carbamylation 
can be considered as a good marker for evaluating hemo-
dialysis efficiency. Being a baseline parameter of dialy-
sis adequacy, Kt/V represents the cleared blood volume 
related to the distribution volume of urea [15].
In renal insufficiency, middle-sized and protein-
bound molecules accumulate in plasma [16–18]. A myriad 
of compounds, called uremic toxins, which are excreted 
by the healthy kidneys under normal condition [19], are 
protein bound. Para-cresol originates from the phenylala-
nine and tyrosine metabolism by intestinal bacteria and 
is partly converted to para-cresyl sulfate (PCS) and para-
cresyl glucuronide (PCG) [20, 21]. It binds to albumin and 
shows structural resemblance to BCG and BCP [21]. This 
compound is a marker for cardiovascular disease in ESRD 
[22, 23]. Indoxyl sulfate (IxS) is a tryptophan metabolite, 
which is converted into indole by intestinal bacteria. In 
the liver, indole is metabolized into IxS [24]. Also indole-
3-acetic acid is produced by intestinal bacteria [21]. 3-Car-
boxy-4-methyl-5-propyl-2-furanpropionic acid (CMPF) 
inhibits binding of drugs to albumin [6]. Thus, besides 
carbamylation of the binding sites for BCP [2], the pres-
ence of uremic toxins may be a confounder of the falsely 
low serum albumin concentrations [4].
Finally, the plasma protein spectrum undergoes changes 
in renal failure. Serum concentrations of α1-acid glycoprotein 
(and in particular the strongly concanavalin A-reactive α1-
acid glycoprotein fractions) are higher in hemodialyzed and 
uremic patients than in control subjects [25]. In patients with 
renal insufficiency, α1-acid glycoprotein is qualitatively dif-
ferent from normal α1-acid glycoprotein [26]. The influence of 
α1-acid glycoprotein on BCG or BCP assays has not yet been 
investigated in patients with ESRD.
In the present study, the dye binding of albumin in 
renal insufficiency will be investigated in detail. The effects 
of the various potential compounds (dialysis efficiency, 
uremic toxins and plasma proteins) will be compared.
Materials and methods
Sixty-two ESRD patients (36 men, 26 women; median age, 71 years; 
IQR, 62–80 years), treated with chronic hemodialysis, were enrolled in 
the study. Blood, sampled before the start of a hemodialysis session, 
was centrifuged (10 min, 3000× g, room temperature), and serum was 
obtained. Routine blood parameters such as urea and creatinine were 
determined. Albumin was assayed using immunonephelometry on a 
BN II nephelometer (Siemens Medical Solutions, Erlangen, Germany) 
as gold standard. In parallel, serum albumin was assayed colorimet-
rically, using BCG- and BCP-based dye binding assays on a Modular 
analyzer (Roche, Mannheim, Germany). In order to compare the rela-
tive binding of both dyes with albumin, the ratio between BCP and 
BCG results was calculated. Acute phase proteins [C-reactive protein 
(CRP) and α1-acid glycoprotein] and plasma protein α2-macroglobulin 
were assayed nephelometrically on a BN II nephelometer (Siemens 
Medical Solutions, Erlangen, Germany), using commercial antisera 
(Siemens Medical Solutions).
Single-pool Kt/V (spKt/V) was calculated according to Daugirdas 
[27]: post post
pre pre
BUN BUN UFspKt/V LN 0.008 t 4 3.5
BUN BUN BW
   
= − − ⋅ + − ⋅ ⋅         , 
where BUNpre and BUNpost are the pre- and posthemodialysis blood 
urea nitrogen concentrations, UF is the ultrafiltration volume and 
BW is the postdialysis body weight. Measured Kt/V values were 
extrapolated to a weekly based Kt/Vweek to account for different dialy-
sis strategies.
In parallel, seven uremic toxins were determined with high-per-
formance liquid chromatography (HPLC): IxS, PCS, PCG, indol-3-ace-
tic acid (IAA), CMPF, hippuric acid (HA) and uric acid (UA). Prior to 
analysis, serum samples were denaturated at 95 °C, followed by filtra-
tion using a 30-kDa cutoff molecular filter (Centri-free Micropartition 
Devices, Amicon Inc., Beverly, MA, USA). For the determination of the 
free fractions, denaturation was preceded by filtration  (Millipore, Bill-
erica, MA, USA). The HPLC analyzers consisted of a Waters  Alliance 
2695 device (Waters, Zellik, Belgium) and two detectors in series: a 
Waters 996 photodiode array detector and a Waters 2475 fluorescence 
detector. The separation was performed at room temperature on a 
reversed-phase XBridge C8 column (3.5 μm, 150 mm × 4.6 mm, Waters) 
with an Ultrasphere ODS guard column (5 μm, 45 mm × 4.6 mm, Beck-
man Instruments, Miami, FL, USA). The mobile phase consisted of a 
50-mM ammonium formate buffer (mobile phase A, pH 3.0) and meth-
anol (mobile phase B). HA and CMPF were analyzed by UV detection 
at 245 and 254 nm, respectively, whereas PCS and PCG (λex = 264 nm, 
λem = 290  nm), and IAA and IxS (λex = 272  nm, λem = 340  nm and 
374  nm, respectively) and the internal standard fluorescein (λex: 
443 nm, λem: 512 nm) were determined by fluorescence detection [28, 
29]. In vitro addition of PCS and IxS to serum of healthy subjects (n = 5) 
was achieved by adding PCS (Sigma, St Louis, MO, USA) and IxS in 
phosphate-buffered saline (0.1 mol/L, pH 7.4) to serum. The study was 
approved by the Local Ethics Committee (2015/0932, Belgian registra-
tion number B670201525559).
Statistical analysis was carried out using the program MedCalc 
version 15.5 (MedCalc Software, Mariakerke, Belgium). Normality of 
distributions was tested using the D’Agostino Pearson test. To inves-
tigate the correlation between two non-normal continuous variables, 
a rank correlation test was carried, whereby Spearman’s rho was cal-
culated. A p-value <0.05  was considered a priori to be statistically 
significant.
Results
The predialysis serum specimens of the hemodialysis 
patients were assayed for albumin using immunon-
ephelometry (range, 27.1–48.5 g/L), BCP and BCG. Both 
Roche dye binding methods showed lower concentrations 
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as compared with the immunonephelometric method 
[mean ± SD, 37.7 ± 4.6 g/L (immunonephelometry), 
31.9 ± 5.7 g/L (BCP) and 36.7 ± 6.9 g/L (BCG)]. The fol-
lowing equations illustrate the relationship between 
the  immunonephelometric method, BCP and BCG: y 
(albumin, BCP, g/L) = 0.5728 (albumin, immunonephelo-
metric method, g/L) + 10.3216 (r = 0.4640, p = 0.0001) and 
y (albumin, BCG, g/L) = 0.5865 (albumin, immunoneph-
elometric method, g/L) + 14.5969 (r = 0.3929, p = 0.0016). 
The BCP/BCG ratio was compared with the concentra-
tions of α1-acid glyco protein, α2-macroglobulin and CRP. 
The observed α1-acid glycoprotein concentration range in 
serum (median, 1.32  g/L; IQR, 0.94 g/L–1.52 g/L) largely 
exceeded the reference range of 0.39–1.15 g/L. The serum 
concentrations of α2-macroglobulin and CRP (refer-
ence value) ranged from 0.6 to 2.6 g/L (1.3–3.0 g/L) and 
from 0.5 to 65  mg/L (<5.0  mg/L), respectively. Regres-
sion analysis revealed a significant correlation between 
the BCP/BCG ratio and the α1-acid glycoprotein protein 
concentration. The regression equation was y (BCP/
BCG ratio) = 0.8920 − 0.227log(α1-acid glycoprotein, g/L), 
r = −0.6279, p < 0.0001 (Figure 1). By contrast, the serum 
CRP and α2-macroglobulin concentrations did not show a 
correlation with the BCP/BCG ratio.
In order to assess the relative importance of the 
various uremic toxins for the BCP/BCG ratio, multiple 
regression was applied in which the BCP/BCG ratio was 
compared with the concentrations of CMPF, free and 
total HA, free and total IAA, free and total IxS, free and 
total PCS, free and total PCG and UA. Among the inves-
tigated uremic toxins, only total PCS showed a signifi-
cant correlation with the BCP/BCG ratio: y (BCP/BCG 
ratio) = 0.8427 + 0.01019 (total PCS, μmol/L), r = 0.3362, 
p = 0.0076 (Figure 2). In vitro addition of PCS (final con-
centration ranging from 0 to 0.2  mmol/L) to serum of 
healthy subjects resulted in a small increase of the BCP/
BCG ratio. In particular, BCP-based albumin concentra-
tions were more affected by adding PCS, in comparison 
with the results obtained with the BCG-based method. As 
expected, addition of IxS did not result in a significant 
change in albumin results.
The BCP/BCG ratio showed a good correlation with 
weekly Kt/V: y (BCP/BCG ratio) = 1013–0.064 (Kt/Vweek), 














Figure 1: Regression analysis of α1-acid glycoprotein and the BCP/BCG 
ratio in serum of hemodialysis patients.
The regression equation is y (BCP/BCG ratio) = 0.8920 − 0.227 
log(α1-acid glycoprotein, g/L), r = −0.6279, p < 0.0001.













Total para-cresyl sulfate, µmol/L
Figure 2: Regression analysis of total para-cresyl sulfate and the BCP/BCG ratio in serum of hemodialysis patients.
The regression equation is y (BCP/BCG ratio) = 0.8427 + 0.01019 (total para-cresyl sulfate, μmol/L), r = 0.3362, p = 0.0076.
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serum showed an effect on the BCP/BCG ratio. Multiple 
regression analysis confirmed that Kt/V and PCS were 
independent predictors of the BCP/BCG ratio. Table 1 sum-
marizes the parameters, which significantly affect the 
BCP/BCG ratio.
Discussion
As illustrated in the present study, the BCP/BCG ratio in 
patients with terminal renal insufficiency may be deter-
mined by multiple factors. The influence of urea on the 
discrepant results between immunonephelometry, and 
BCP has already been demonstrated, which is attribut-
able to carbamylation [2]. A good correlation between the 
percentage of carbamylated albumin and the global car-
bamylation of blood proteins in uremic subjects has been 
observed [30]. Due to the carbamylation-induced struc-
tural changes, incorrect protein function may lead to a 
variety of health problems such as cardiovascular disease, 
the most common cause of death in patients with renal 
failure [12, 30]. Carbamylation of proteins by elevated 
blood urea concentrations can activate mesangial cells to 
a profibrogenic phenotype, accelerating the progression 
to kidney failure [31]. In addition, carbamylated LDL plays 
a pivotal role in atherosclerosis [32].
In a multiple regression model, only Kt/Vweek and total 
PCS remained significant independent confounders of the 
BCP/BCG ratio. Both parameters highlight the association 
between the BCP/BCG ratio and the presence of circulating 
toxins in renal insufficiency. A fairly negative correlation 
between Kt/V and the BCP/BCG ratio was demonstrated. 
This is in agreement with the observations of Kok et al. [2], 
who linked the BCP/BCG ratio with carbamylation. It is of 
note, however, that although Kt/V is reflecting urea kinet-
ics, it is not representative for the kinetics of other uremic 
toxins, of which concentrations were found more depend-
ing on protein equivalent of nitrogen appearance and/
or residual renal function [33]. In addition, it has already 
been demonstrated that no interfering substance is 
present or introduced during hemodialysis as comparable 
BCP-based albumin concentrations were measured in pre- 
and posthemodialysis plasma samples [2].
Independent from carbamylation, the BCP/BCG ratio 
partly depended on the serum concentration of uremic 
toxins. Among the spectrum of investigated toxins (free 
and total IAA, PCS, PCG, HA, IxS and total CMPF), impor-
tant differences were observed. Only total PCS correlated 
significantly with the BCP/BCG ratio. This might imply 
that BCP has affinity for the same albumin binding site as 
PCS has (Sudlow’s site II), in contrast to CMPF (Sudlow’s 
site I). From previous binding competition experiments, 
clearly showing superior binding capacity of PCS versus 
IxS, IAA and HA, it is however hard to explain that the 
correlation between BCP and PCS is due to mutual com-
petition [34]. The in vivo results were confirmed by in vitro 
spiking of PCS to human serum. In contrast to BCP, BCG-
based assays were less affected by PCS. The affinity con-
stant of PCS towards albumin is 6 μM [35].
Also the altered protein spectrum in renal insuffi-
ciency and in particular the increased serum α1-acid gly-
coprotein concentrations may play a role in explaining the 
BCP/BCG ratio in hemodialysis patients. The correlation 
between the BCP/BCG ratio, CRP and α1-acid glycoprotein 
points towards a link between inflammatory reactions 
[36] and the BCP/BCG ratio. In agreement with the find-
ings of Xu et al. [10], α1-acid glycoprotein was identified 
as a dye binding protein. However, in the multiple regres-
sion analysis, α1-acid glycoprotein was not withheld as an 
independent confounder of the BCP/BCG ratio. In hemodi-
alysis, the values exceed the reference range. In contrast 
to the findings of Ueno et  al. [8], the α2-macroglobulin 
concentration did not affect the BCP/BCG ratio. This can 
be explained by the fact that in patients with a nephrotic 
syndrome, the α2-macroglobulin/albumin ratio is higher 
than in the hemodialysis population.
In the present study, we have demonstrated that the 
ratio of serum albumin concentrations obtained with BCP 
and BCG is affected by multiple factors. Next to carbamyl-
ation, also uremic toxins (in particular PCS) and α1-acid 
glycoprotein affect the binding.
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Table 1: Multiple regression analysis with the BCP/BCG ratio as a 
dependent variable.
    β (SE)   p-Value
BCP/BCG ratio   Kt/V   −0.0618 (0.0102)   <0.0001
r2 = 0.57, p < 0.001  Total para-
cresyl sulfate
  0.0083 (0.0032)   0.013
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